AI-Based Safety, Explainability, and Risk Assessment in Gene and Cell Therapies
- 14 August 2026
- book chapter
- Published by IGI Global Scientific Publishing
- p. 379-406
Abstract
AI is ushering in a significant paradigm shift across gene and cell therapies (G&CTs), advancing the field away from conventional, trial-and-error treatments toward precision molecular corrections. Although could treat a wide variety of diseases, these complex, living therapeutics raise enormous safety and manufacturing concerns such as genotoxicity, insertional mutagenesis, immunogenicity and extreme batch-to-batch heterogeneity. To address the high-stakes clinical translation while promoting safety, you must dismantle the “black-box” dilemma by utilizing Explainable AI (XAI) frameworks such as SHAP and LIME or glass-box based modeling to ensure biological traceability and regulatory compliance. Even more, AI maximizes biomanufacturing through real-time Process Analytical Technology (PAT), unsupervised anomaly detection, and predictive cold-chain logistics. In order to deploy these algorithmic tools successfully, we need validation protocols with continuous monitoring for model drift; inclusive multi-ethnic datasets to eliminate systemic bias; and adaptive regulatory mechanisms.Keywords
This publication has 45 references indexed in Scilit:
- Machine Learning‐Enabled Drug‐Induced Toxicity PredictionAdvanced Science, 2025
- Nongenerative Artificial Intelligence in Medicine: Advancements and Applications in Supervised and Unsupervised Machine LearningLaboratory Investigation, 2024
- Emerging Vulnerabilities and Risks in Therapy Manufacture: Cell and Gene Therapy Production as an Emerging Domain of Critical InfrastructureEuropean Journal of Risk Regulation, 2024
- Biomanufacturing in gene and cell therapyMolecular Therapy - Methods & Clinical Development, 2024
- Gene therapy: principles, challenges and use in clinical practiceWiener klinische Wochenschrift, 2024
- Explainable AI for clinical and remote health applications: a survey on tabular and time series dataArtificial Intelligence Review, 2022
- Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperMolecular Therapy - Methods & Clinical Development, 2022
- Unbox the black-box for the medical explainable AI via multi-modal and multi-centre data fusion: A mini-review, two showcases and beyondInformation Fusion, 2022
- Artificial Intelligence for Drug Toxicity and SafetyTrends in Pharmacological Sciences, 2019
- Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapyCancer Medicine, 2019